Navigation Links
Plasma-based treatment goes viral

Life-threatening viruses such as HIV, SARS, hepatitis and influenza, could soon be combatted in an unusual manner as researchers have demonstrated the effectiveness of plasma for inactivating and preventing the replication of adenoviruses.

When exposed to plasma the fourth state of matter in addition to solids, liquids and gases for a period of just 240 seconds, it was found that only one in a million viruses could still replicate practically all were inactivated.

The study, published in IOP Publishing's Journal of Physics D: Applied Physics, is one of the first to concentrate specifically on viruses and builds on research that has already shown the usefulness of plasma in eradicating bacteria from skin ( and sterilising water (

Within a hospital environment, a plasma generating device could realistically rid hands of potentially lethal viruses that relay on a host organism to replicate and spread. In the long-term, plasma could be inhaled directly to treat viruses in the lungs, or applied to blood outside of the body to remove any viruses before transfusion.

The researchers, from the Max-Planck Institut fr extraterrestrische Physik and Technische Universitt Mnchen, specifically chose adenoviruses to examine as they are one of the most difficult viruses to inactivate. Illnesses resulting from this specific virus, for example, can only be managed by treating symptoms and complications of the infection, rather than targeting the actual virus itself.

Adenoviruses predominantly cause respiratory illnesses such as pneumonia and bronchitis and are hard to inactivate as the whole virus is encased in a protein layer, helping it to remain physically stable and tolerate moderate increases in heat and pH.

In this study, the adenoviruses were diluted to specific concentrations and then exposed to plasma for 240 seconds, before being incubated for an hour. A control group of adenoviruses were given the exact same treatment apart from the plasma exposure.

Two separate cell lines were then infected with the two sets of adenoviruses: the ones that were treated with plasma and the control group. To test whether a cell had the virus or not, the researchers programmed the virus to produce a protein that fluoresced green when a specific type of light was shone onto it.

Whilst the exact mechanisms behind the plasma's impressive effects are relatively unknown, it is thought that they are a result of a combination of reactions between the plasma and surrounding air, which create similar species to the ones found in our own immune system when under microbial attack.

Contact: Michael Bishop
Institute of Physics

Related biology news :

1. Phase I trial begins using gene therapy and bone marrow stem cells in the treatment of brain cancer
2. Novel monoclonal antibody offers potential treatment for tumors resistant to VEGF therapy
3. Fish flu: Genetics approach may lead to treatment
4. Possible treatment target found for main cause of severe liver disease in kids
5. Texas A&M center confronts antibiotic crisis with potential new bacterial treatment
6. Evidence for spinal membrane as a source of stem cells may advance spinal cord treatment
7. Dormant malaria parsites in red blood cells may contribute to treatment failure
8. British study may improve glaucoma assessment and treatment
9. Xencor Initiates Phase 1 Study of XmAb®5871 Therapeutic Antibody for the Treatment of Autoimmune Diseases
10. UT Southwestern research could lead to new treatments for IBD, viral infections
11. Cracking breast cancers genetic code may lead to new treatments
Post Your Comments:
(Date:11/26/2015)... -- Research and Markets ( ) has announced ... Technology and Patent Infringement Risk Analysis" report to ... --> Fingerprint sensors using capacitive technology represent a ... vendor Idex forecasts an increase of 360% of the ... of the fingerprint sensor market between 2014 and 2017 ...
(Date:11/18/2015)... 2015  As new scientific discoveries deepen our understanding ... healthcare providers face challenges in better using that knowledge ... addition, as more children continue to survive pediatric cancer, ... old age. John M. Maris, M.D ., ... Philadelphia (CHOP) . --> John M. ...
(Date:11/17/2015)... -- Vigilant Solutions announces today that Mr. Dick W. ... --> --> Mr. Boyce ... at TPG Capital, one of the largest global investment ... revenue.  He founded and led TPG,s Operating Group, which ... 1997 to 2013.  In his first role, he served ...
Breaking Biology News(10 mins):
(Date:11/30/2015)... 30, 2015  Champions Oncology, Inc. (CSBR), engaged in ... personalize the development and use of oncology drugs, today ... will be presenting at the LD MICRO Investor Conference ... Time (PST).  The conference, held at the Luxe Sunset ... , will feature 200 small/micro-cap companies and is ...
(Date:11/30/2015)... JACKSONVILLE, Florida , November 30, 2015 ... company specializing in the development of innovative peptide and ... & metastatic disease, today announced it will be presenting ... Event on December 1, 2015 at 2.30 PM PT. ... member and Strategic Advisor will be giving the presentation ...
(Date:11/30/2015)... -- Aytu BioScience, Inc. (OTCQB: AYTU), a commercial-stage specialty healthcare ... at two upcoming investor conferences. Aytu is scheduled to ... to be held December 3, 2015, and at LD ... 2 nd & 3 rd , 2015 in ... via webcast. Josh Disbrow , Chief Executive ...
(Date:11/30/2015)... Florida and MAGDEBURG, Germany , ... of NeuroRehabilitation (ECNR) in Vienna, Austria ... 3rd European Congress of NeuroRehabilitation (ECNR) in ... --> NovaVision, a wholly owned subsidiary of Vycor ... European version of its Internet-delivered NovaVision Therapy Suite at the ...
Breaking Biology Technology: